ELISpot and FluoroSpot assays are techniques which are used to assess the antibody reactivity at the cellular level. They are extensively used by hospitals as well as research institutes for early detection of various diseases, most commonly for tuberculosis or viral infection. FluoroSpot assay is an adaptation of the ELISpot assay and has gained widespread acceptance. Market Research Future (MRFR) has extensively studied the patterns and trends governing the global ELISpot and FluoroSpot assay market analysis forecast between 2018-2023 in a detailed report. MRFR has asserted that the market is likely to reach USD 287 Mn at a splendid CAGR of 16.2% over the forecast period. The market stood at USD 135 Mn in 2017.
ELISpot and FluoroSpot assays are outstandingly sensitive and are easy to perform due to which they find extensive application in research studies concerning vaccine development, allergies, cancer, and other research purposes. The surge in the incidence rate of chronic diseases has been instrumental in the growth of the market. Increasing disease burden necessitate the development of vaccines which induce demand for ELISpot and FluoroSpot assays. Additionally, the growing occurrence of oncological diseases has further boosted the market growth. ELISpot and FluoroSpot Market Trends and Technological advances in techniques have resulted in increased sensitivity, robustness, and ease of performance which has increased the adoption rate of these techniques. Other factors motivating growth within the market include an increase in a number of clinical trials and increasing healthcare expenditure across the globe. However, the growth of the market might be hindered by factors such as lack of techniques with adequate knowledge to perform these tests and the availability of alternative detection technologies.
Some of the key players in the global ELISpot and FluoroSpot Assay market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.
The Global ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The ELISpot and FluoroSpot Assay market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.
Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the ELISpot and FluoroSpot Assay market in this region. Asia-Pacific was estimated to be the fastest growing region for the global ELISpot and FluoroSpot Assay market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.
The Middle East and Africa holds the least share in the global ELISpot and FluoroSpot Assay market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/elispot-and-fluorospot-assay-market-6948